作者
Neil H. Segal,J. Tie,S. Kopetz,M.P. Ducreux,E. Chen,R. Dienstmann,A. Hollebecque,M. Reilley,M.E. Elez Fernandez,J. Cosaert,Joan E. Cain,M. Hernandez,N. Hewson,Z.A. Cooper,M. Dressman,J. Tabernero
摘要
Despite advances in the treatment of mCRC combining chemotherapy regimens with biologics, most patients (pts) still progress within 11 months of receiving 1L chemotherapy. Addition of novel therapies to the standard of care (SoC) to improve antitumor activity is urgently needed. The randomized part 2 of COLUMBIA-1 (NCT04068610) evaluated the safety and efficacy of combining SoC (bevacizumab [BEV] + FOLFOX) with the PD-L1 inhibitor durvalumab (D) and the anti-CD73 monoclonal antibody oleclumab (O). Pts with previously untreated, MSS-mCRC and ECOG PS ≤1 received either SoC alone or SoC + D (1500 mg, Q4W) + O (3000 mg Q2W x4 then Q4W) in the experimental arm (EXP). The primary endpoint was objective response rate (ORR) per investigator assessed RECIST v1.1. As of 10 Dec 2021, 52 pts were enrolled, of whom 51 were response evaluable. The confirmed ORR with SoC was 44.0% (95% confidence interval [CI], 24.4–65.1%) compared to 61.5% (95% CI, 40.6–79.8%) in the EXP arm. Median OS was not reached (SoC) vs 19.1 mos (EXP); median PFS was 11.1 mos (SoC) vs 10.9 mos (EXP; Table). Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 76.9% of pts in SoC and 65.4% EXP. Fatal TEAEs (all unrelated) were observed in 3 pts in the EXP arm: 1 with sepsis and 2 with intestinal perforation. One pt with intestinal perforation deemed related to BEV experienced fatal peritonitis. In the SoC arm, there was a single fatal COVID-19 TEAE. The most frequent treatment-related AEs in the EXP arm were diarrhea (38.5%), peripheral sensory neuropathy (38.5%) and fatigue (26.9%). There was no identified association between CD73 expression and clinical benefit. Addition of D + O to FOLFOX + BEV SoC showed a moderate response increase without PFS benefit vs SoC alone. Safety was consistent with known safety profiles.Table: 160PRECIST v1.1Response Evaluable PopulationSoC (n=25)EXP (n=26)Best Overall Response, n (%)Confirmed CR01 (3.8)Confirmed PR11 (44.0)15 (57.7)SD12 (48.0)7 (26.9)Unconfirmed PR3 (12.0)1 (3.8)PD1 (4.0)2 (7.7)Unknown/not evaluable1 (4.0)1 (3.8)ORR, n (%) [95% CI %]11 (44) [24.4, 65.1]16 (61.5) [40.6, 79.8]Disease Control, n (%) [95% CI %]23 (92.0) [74.0, 99.0]23 (88.5) [69.8, 97.6]Median DoR, mos (95% CI %)7.6 (3.7, NE)10.3 (5.8, 14.9)Median PFS, mos (95% CI %)**11.1 (7.3, 19.3)10.9 (6.9, 15.1)PFS rate at 12 mos, % (95% CI %)**35.9 (16.2, 56.2)36.1 (17.1, 55.5)Median OS, mos (95% CI %)**NR (18.2, NE)19.1 (10.6, NE)*NE=Not Estimable; **ITT Population: SoC (n=26), EXP (n=26) Open table in a new tab